BRAF and melanoma: We show that BRAF-mutant melanoma cells with acquired resistance to BRAF inhibition have a heterogeneous metabolic profile that is characterised by an overall lower glycolytic, bioenergetic and phospholipid metabolic activity compared to sensitive cells.